Startup profile · funding coverage
BioAge Labs funding, valuation and investors
Clinical-stage biotech targeting metabolic disease and aging biology (public: BIOA).
Keep track of BioAge Labs
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series D
$170M · February 2024
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$170M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
public
public
Investors in latest funding
Other: Andreessen Horowitz
Latest tracked event: IPO (September 2024). It is shown separately because it is not counted as disclosed equity funding.
Overview
BioAge Labs is a clinical-stage biotech targeting metabolic disease and aging biology using AI-driven target discovery from longitudinal health records. Lead asset azelaprag is in obesity trials with an Eli Lilly partnership. The company raised a $170M Series D in 2024 and went public on Nasdaq (BIOA) in September 2024. a16z Bio + Health, Khosla Ventures, F-Prime, and Third Rock are among crossover backers.
Why BioAge Labs is interesting
AI-driven target discovery from longitudinal health records; lead asset azelaprag in obesity trials with Lilly partnership — a16z among crossover health backers pre-IPO.
Product & use cases
Clinical-stage biotech using AI on longitudinal health data to discover aging/metabolic targets — lead program azelaprag in obesity with Lilly partnership.
- Obesity and metabolic disease therapeutics
- Aging biology target discovery from human datasets
- Pharma partnership on clinical-stage assets
Key facts
- Series D (Feb 2024): $170M led by Sofinnova; a16z Bio + Health among existing investors (Reuters)
- IPO (Sep 2024) on Nasdaq following obesity-program partnership momentum with Eli Lilly
- Co-investors not in VCT directory: Sofinnova Investments, Longitude Capital, RA Capital, Lilly Ventures
- Source: https://ir.bioagelabs.com/news-releases/news-release-details/bioage-announces-170-million-oversubscribed-series-d-financing
Funding history (newest first)
IPO
2024-09Source: https://ir.bioagelabs.com/
Investors in our directory
Funds linked from BioAge Labs's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: BioAge Labs differentiates through focused product scope and a16z-backed GTM in its category — see competitors for tradeoffs vs. incumbents.
BioAge Labs operates in a competitive category where incumbents have distribution but startups win on workflow fit. See named competitors for honest better/worse notes; we do not invent market share.
-
Altos Labs adjacent
Aging biology focus; different pipeline stage and approach.
-
Calico adjacent
Google-backed aging research; less clinical-stage public exposure.
-
Novartis obesity programs incumbent
Big pharma in same therapeutic area as azelaprag.
Notable stories
- BioAge IPO'd on Nasdaq (BIOA) in Sep 2024 after Lilly partnership momentum on obesity program azelaprag.
Industries
Market / IPO context
Ticker: BIOA (NASDAQ)
IPO status: public
Editorial / static context — not a live quote.
FAQs about BioAge Labs
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.